Pfizer to build $465m sterile injectable plant in Michigan
pharmafile | July 25, 2018 | News story | Manufacturing and Production, Research and Development | Michigan, Pfizer, US, manufacturing, pharma
Pfizer has unveiled plans to invest $465 million to build a new sterile injectables plant in Portage, Michigan, saying that the facility will create 450 jobs and “strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around the world”.
The new facility is set to cover 400,000 square feet and will be focused on modular aseptic processing (MAP), utilising multiple, self-contained modular manufacturing lines, and will, according to the company, incorporate “the most technically advanced aseptic manufacturing equipment, systems and design”. It bolsters Pfizer’s operations in Kalamazoo County, where it already employs 2,200 people
“This investment is part of our overall plan announced in January to invest approximately $5 billion in US-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act. During the next six years, we expect to invest approximately $1.1 billion in Kalamazoo County – which is in addition to the $1 billion we have invested in the site over the past decade,” said Ian Read, Chairman and Chief Executive Officer. “Every day, we strive to enhance our ability to bring medicines to the patients who need them, and the new facility we are building in Michigan will help us continue to deliver therapies that significantly improve people’s lives.”
Ron Perry, Site Leader for the Portage plant, also added: “Sterile drug product manufacturing is incredibly complex. This contemporary facility will combine cutting-edge technology and a highly talented workforce to assure we remain a trusted and reliable supplier of these therapies to patients.”
Ground is projected to be broken on the project in Spring 2019, to be completed by 2021 and with production to commence in 2024.
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …
